An overview of kinase downregulators and recent advances in discovery approaches

Since the clinical approval of imatinib, the discovery of protein kinase downregulators entered a prosperous age. However, challenges still exist in the discovery of kinase downregulator drugs, such as the high failure rate during development, side effects, and drug-resistance problems. With the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Beilei, Wu, Hong, Hu, Chen, Wang, Haizhen, Liu, Jing, Wang, Wenchao, Liu, Qingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685278/
https://www.ncbi.nlm.nih.gov/pubmed/34924565
http://dx.doi.org/10.1038/s41392-021-00826-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685278/
https://www.ncbi.nlm.nih.gov/pubmed/34924565
http://dx.doi.org/10.1038/s41392-021-00826-7

Ejemplares similares